REOLYSIN shown to benefit some sarcoma patients

A vision screening law targeting Florida drivers age 80 and older appears to be associated with lower death rates from motor vehicle collisions in this age group, despite little evidence of an association between vision and car crashes, according to a report in the November issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Full Post: Vision screening law for older Floridians associated with lower fatality rates in car crashes

New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives.

Dr. Monica Mita of the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas, delivered her findings at both the Connective Tissue Oncology Society (CTOS) annual meeting in London, U.K. and the Chemotherapy Foundation Symposium XXVI in New York in November 2008. Her oral presentation discussed the interim results of a U.S. Phase II trial investigating intravenous REOLYSIN in patients with bone and soft tissue sarcomas metastatic to the lung.

“The standard treatment for this type of sarcoma is chemotherapy, but prognosis is poor since there is no cure,” said Dr. Mita. “Patients with only a few months to live face poor quality of life because chemotherapy treatments are so harsh. The goal is to introduce less invasive approaches that help extend life and provide patients with a better quality of life.”

REOLYSIN, being developed by Oncolytics Biotech Inc, a Calgary-based company, preferentially replicates in cancer cells with an activated RAS pathway. Approximately two thirds of all cancers have an activated RAS pathway, including most metastatic disease. The reovirus is a segmented double-stranded RNA virus that causes only mild illness in humans. Although the virus replicates robustly in cancer cells expressing Ras, a cancer signaling pathway, it spares normal cells. Viral replication within cancer cells causes them to burst open, releasing more virus to infect other cells.

To date, thirty-five patients have been enrolled in the study, and twenty-nine are evaluable. A fifth (six of twenty-nine) of the evaluable patients experienced stable disease (SD) for more than sixteen weeks, an important benchmark for marking drug activity in these hard-to-treat cancers. Dr. Mita and her team of investigators concluded that the study has met its established objectives, and that enrollment will continue to the full fifty-two patients.

One trial patient with synovial sarcoma (a rare form of cancer that usually occurs near to the joints of the arm or leg) has stable disease after seventeen cycles of treatment, and continues on trial. One patient with Ewing’s sarcoma (a type of bone tumor) experienced stable disease after nine cycles of REOLYSIN and continues on trial. One patient with malignant fibrous histiocytoma experienced stable disease after seven cycles (with a tumor resection after achieving stable disease at cycle four). This patient also continues to be treated in the trial. Other patients with rare types of tumors such as leiomyosarcoma, chordoma and unspecified spindle cell sarcoma have experienced stable disease for more than sixteen weeks.

“A 21% response in a patient population where nothing works at all is a major advance,” says Oncolytics Biotech’s CEO Dr. Brad Thompson, “particularly as the only side effects to date have been relatively mild.”

The virus is delivered through cycles of daily forty-minute infusions for a week at a time, with gaps of three weeks in between.


Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled “Reovirus for the Treatment of Neoplasia.” The patent includes claims to pharmaceutical compositions containing reovirus. “This U.S. patent expands and strengthens our proprietary position for REOLYSIN(R),” said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. “The

Full Post: Oncolytics Biotech issued new U.S. patent “Reovirus for the Treatment of Neoplasia”

Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines

Full Post: Ewing sarcoma treatment ineffective, despite promising laboratory data

Oncolytics Biotech Inc. today announced that it has been granted its 30th U.S. Patent, # 7,452,723, entitled “Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders. “The allowed claims relate to kits comprised of reovirus and an immune suppressive agent that are designed to prevent reovirus recognition by the immune system. “This

Full Post: Oncolytics Biotech issued 30th U.S. patent

Biopure Corporation has announced that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company’s oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)]. In the proposed trial Hemopure would be studied for use in the treatment of life-threatening

Full Post: Biopure submits IND for trial in patients with acute myeloid leukemia

Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period

Full Post: Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma